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DOES THE GENETIC INFORMATION 
NONDISCRIMINATION ACT OF 2008 OFFER 
ADEQUATE PROTECTION? 
INTRODUCTION 
With the advancement of medicine and technology in 
genetics, new forms of discrimination have emerged in both the 
healthcare system and the workplace. In an attempt to 
minimize the costs associated with insurance premiums and 
sick leave, some employers have chosen to terminate employees 
who are genetically predisposed to certain conditions.1 For 
example, Kim, a social worker, mentioned to her co-workers 
that she had cared for her mother who passed away from 
Huntington’s disease.2 Due to the genetic nature of the illness, 
this passing comment indicated that Kim had a 50% chance of 
also developing the debilitating disorder.3 Despite her record of 
strong job performance, Kim was discharged from her position 
only a week after her revelation.4 For Gary, his employer 
administered secret genetic testing in an attempt to determine 
which employees were genetically predisposed to developing 
Carpal Tunnel Syndrome.5 When Gary refused to partake in 
the genetic screening, his employer initiated disciplinary 
  
 1 Rivka Jungreis, Note, Fearing Fear Itself: The Proposed Genetic 
Information Nondiscrimination Act of 2005 and Public Fears About Genetic 
Information, 15 J.L. & POL’Y 211, 218 (2007). 
 2 NAT’L P’SHIP FOR WOMEN & FAMILIES ON BEHALF OF THE COAL. FOR 
GENETIC FAIRNESS, FACES OF GENETIC DISCRIMINATION: HOW DISCRIMINATION 
AFFECTS REAL PEOPLE 5 (2004), available at http://www.nationalpartnership.org/ 
site/DocServer/FacesofGeneticDiscrimination.pdf. 
 3 Id. 
 4 Id. 
 5 Id. 
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proceedings to terminate his employment.6 Likewise, though 
David has an approximately 16% chance of having a cancerous 
genetic mutation,7 he is waiting for discrimination protection 
before taking the necessary test.8 Not surprisingly, for many 
Americans, there is a growing wariness toward genetic 
screening out of fears of discrimination in the work place.  
The nationwide fear of genetic testing has detrimental 
consequences not only for the physical health of individuals, 
but also for scientific development.9 Without participants to 
enroll in genetic studies, researchers cannot improve the 
accuracy of genetic screening, since large data pools are often 
required to link gene variants to health conditions.10 In 
addition, individuals put their physical well-being at risk by 
foregoing the opportunity to take additional measures to 
monitor or avoid conditions for which they are genetically 
predisposed.11 In one frightening situation, the parents of a 
young girl learned that their family had a history of a Factor V 
Leiden mutation, a condition associated with a heightened risk 
for blood clots.12 The family was advised to wait until Congress 
passed legislation protecting against genetic discrimination 
before testing their daughter for the mutation.13 As a result of 
waiting, their daughter nearly died after suffering a massive 
blood clot.14 
In response to the growing concern about genetic 
discrimination in the workplace,15 Congress passed the Genetic 
Information Nondiscrimination Act of 2008 (“GINA”).16 
Arguably, this new legislation will allow Americans to take 
greater advantage of genetic testing opportunities and to 
  
 6 Id. 
 7 Malorye Allison, Industry Welcomes Genetic Information 
Nondiscrimination Act, 26 NATURE BIOTECHNOLOGY 596, 597 (2008). 
 8 Id. 
 9 Susannah Baruch & Kathy Hudson, Civilian and Military Genetics: 
Nondiscrimination Policy in a Post-GINA World, 83 AM. J. HUM. GENETICS 435, 436 
(2008). 
 10 Id. 
 11 Id. 
 12 Id. 
 13 Id. 
 14 Id. 
 15 Kathy L. Hudson et al., Keeping Pace with the Times—The Genetic 
Information Non-discrimination Act of 2008, 358 NEW ENG. J. MED. 2661, 2661 (2008); 
Anne Bond Emrich, New Law Will Protect Genetic Information, GRAND RAPIDS BUS. J., 
Oct. 29, 2008, at S9. 
 16 IOMA, Employer Advocates Remain Wary of Genetic Bias Law’s Potential 
Effects, 8 MANAGING BENEFITS PLANS 1, 1 (2008) [herinafter Employer Advocates]. 
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receive more personalized medical care.17 For health insurance 
providers, GINA bars the use of an applicant’s genetic 
information when making policy enrollment or coverage 
decisions.18 Furthermore, the Act addresses potential genetic 
discrimination in the workplace by prohibiting employers from 
using genetic information when making decisions related to the 
terms and conditions of employment.19  
This Note argues that GINA was a necessary law in 
light of this country’s history of discrimination on the basis of 
genetic information. Since prior federal laws, such as the 
Americans with Disabilities Act (the  
“ADA”), Title VII of the Civil Rights Act of 1964 (the “Civil 
Rights Act”), and the Health Insurance Portability and 
Accountability Act of 1996 (“HIPAA”) do not adequately protect 
employees from genetic discrimination, GINA now offers relief 
to employees who fall victim to discrimination based on a 
predisposition to a genetic disease. However, this legislation is 
only the first step in preventing discrimination by employers 
using genetic information. Indeed, the bill has not gone far 
enough to protect individuals and their families. Consequently, 
as science and technology continue to advance, amendments to 
GINA will be needed in order to provide full protection to 
affected individuals. 
Part I of this Note presents a basic overview of genetic 
testing. Part II examines the historical background of GINA 
with specific instances of genetic discrimination as well as 
quantitative evidence of the current fear of discrimination 
based on genetic predisposition to an illness. In addition, Part 
II examines the gaps in federal legislation prior to GINA and 
argues that the ADA, Title VII, and HIPAA did not provide 
adequate protection from discrimination based on one’s genes. 
Part III of this Note describes the scope of protection provided 
to employees by GINA. Finally, Part IV concludes that GINA 
fails to fully address the issue of genetic discrimination in the 
workplace, and, as such, additional protections are required.  
  
 17 Emrich, supra note 15. 
 18 COALITION FOR GENETIC FAIRNESS, WHAT DOES GINA MEAN?: A GUIDE TO 
THE GENETIC INFORMATION NONDISCRIMINATION ACT 3, 7 (2008), available at 
http://www.geneticfairness.org/GINAPublication111008.pdf. 
 19 Id. at 3, 9. 
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I. A BRIEF INTRODUCTION TO GENETIC TESTING 
Genetic testing is an advanced method of diagnosis 
made available by the completion of the Human Genome 
Project.20 Simply put, a gene is a segment of DNA that stores 
our hereditary information in cells.21 Through genes, parents 
pass biological information and physical traits such as hair 
color and height to their children.22 In particular, genes contain 
the “recipes” for protein creation and “supply the structural 
components of all our cells and tissues as well as specialized 
enzymes for all essential chemical reactions.”23 These proteins 
enable genes to determine how well our bodies function and 
interact with the environment, for example, fighting infections 
and processing food.24 It is estimated that each person has 
anywhere from 20,000-25,000 genes.25 
The unit of information in DNA is the “base,” which is 
composed of adenine, thymine, cytosine, or guanine—“A,” “T,” 
“C,” or “G,” respectively.26 In any two individuals, the base 
sequence is estimated to be at least 99% identical.27 Variation 
in DNA sequence accounts for some physical differences 
between people, and, in some cases, for differences in 
susceptibility to disease.28 Rare sequence variations, called 
  
 20 Hudson et al., supra note 15, at 2661. The Human Genome Project was 
completed in 2003. Id. 
 21 Denise Casey, What Can the New Gene Tests Tell Us? 36 JUDGES’ J. 14, 14-
15 (1997), available at http://www.ornl.gov/sci/techresources/Human_Genome/publicat/ 
judges/judge.html (“In humans and other higher organisms, a DNA molecule consists of 
two ribbon-like strands that wrap around each other, resembling a twisted ladder. The 
ladder rungs are made up of chemicals called bases, abbreviated A, T, C, and G. Each 
rung consists of a pair of bases, either A and T or C and G. We have three billion base 
pairs (six billion bases) of DNA in most of our cells; this is our genome. With the 
exception of identical twins, the sequence of the bases—the order of As, Ts, Cs, and 
Gs—is different for everyone, which is what makes each of us unique. Variation in base 
sequence, along with environmental factors, accounts for all our diversity, including 
disease.”). 
 22 Paul Steven Miller, Is There a Pink Slip in my Genes? Genetic 
Discrimination in the Workplace, 3 J. HEALTH CARE L. & POL’Y 225, 228 (2000). 
 23 Casey, supra note 21, at 14. 
 24 Id. 
 25 Human Genome Program, U.S. Dep’t Energy, Human Genome Project 
Information, http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml (last 
visited Jan. 16, 2010); Better Health Channel, Genes and Genetics, 
http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/Genes_and_genetics 
(last visited Jan. 16, 2010). 
 26 Genetics Home Reference, What is DNA?, http://ghr.nlm.nih.gov/handbook/ 
basics/dna (last visited Jan. 16, 2010). 
 27 Id. 
 28 Casey, supra note 21, at 16. 
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mutations, can vastly increase the risk of certain diseases by 
producing “faulty proteins that function at less-than-normal 
levels or those that are completely nonfunctional . . . .”29 
The Human Genome Project enabled scientists to search 
for genes associated with diseases such as cystic fibrosis and 
Huntington’s disease.30 By far, the most immediate and 
practical application to come out of the Project was the genetic 
test, which inspects “DNA sample[s] for mutated sequences.”31 
Today, over 1,100 genetic tests are available which can be used 
for carrier testing, prenatal genetic testing, preimplantation 
genetic testing, newborn genetic screening, genome scanning,32 
“presymptomatic testing for predicting adult-onset disorders 
such as Huntington’s disease, presymptomatic testing for 
estimating the risk of developing adult-onset cancers and 
Alzheimer’s disease, confirmational diagnosis of a symptomatic 
individuals, and forensic/ identity testing.”33  
Diagnostic testing explains why a person has symptoms 
of a disease and can also be used to confirm a diagnosis based 
on these symptoms.34 Whereas presymptomatic testing can 
determine whether a person at risk for a disease such as 
Huntington’s has actually inherited the corresponding gene,35 
predictive testing can be used to determine whether a person 
not known to be at risk is in fact likely to develop a genetically 
based disease, such as particular forms of cancers.36 For 
parents, carrier testing can determine whether a person carries 
  
 29 Id. “Sometimes only a tiny change in DNA sequence will lead to a serious 
disease. The substitution of just a single base, for example, leads to sickle cell 
anemia. . . . Too many repetitions of a particular sequence of three DNA bases can 
doom a person to Huntington’s disease, a fatal neurological disorder; Fragile X 
syndrome, the most common form of inherited mental retardation; or myotonic 
dystrophy, a muscle-wasting disease.” Id. 
 30 Id. at 18. 
 31 Human Genome Program, U.S. Dep’t Energy, Gene Testing, 
http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetest.shtml (last 
visited Jan. 16, 2010). “For some types of gene tests, researchers design short pieces of 
DNA called probes, whose sequences are complementary to the mutated sequences. 
These probes will seek their complement among three billion pairs of an individual’s 
genome. If the mutated sequence is present in the patient’s genome, the probe will bind 
to it and flag the mutation.” Id. 
 32 Id.  
 33 Casey, supra note 21, at 17. 
 34 NIH, U.S. Dep’t Health & Human Servs., Genetics Home Reference, What 
are the Types of Genetic Tests?, http://ghr.nlm.nih.gov/handbook/testing/uses (last 
visited Jan. 16, 2010). 
 35 Id. 
 36 Id. 
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a gene that, if passed to a child, will result in disease.37 These 
tests can help people make informed choices about their 
personal health. However, evidence demonstrates that many 
Americans avoid taking advantage of these scientific 
developments for fear that non-favorable results could lead to 
discrimination by their employers, insurers, or healthcare 
providers.38 
II. LEGISLATIVE BACKGROUND OF THE GENETIC 
INFORMATION NONDISCRIMINATION ACT OF 2008 
Senator Edward Kennedy of Massachusetts proclaimed 
that the Genetic Information Nondiscrimination Act of 2008 
was “the first major new civil rights bill of the new century.”39 
Passage of this bill was no easy feat, and required thirteen 
years of congressional debate regarding the need for federal 
legislation to prevent abuse of individuals’ genetic 
information.40 Throughout the debate, insurers and employers 
argued that existing laws provided adequate protection for 
individuals and that the passage of GINA would only create 
confusion and unnecessary costs.41 Furthermore, opponents 
expressed concern that the act was overly broad and that its 
definition of “genetic information” would require employers to 
provide health coverage for far too many genetic disorders.42 In 
addition, some challenged the bill on the basis that genetic 
discrimination did not occur in the workplace, as evidenced by 
the limited number of documented cases.43 Likewise, employers 
maintained that in some situations access to genetic 
information is crucial to make important employment 
  
 37 Id. 
 38 Lauren J. Sismondo, GINA, What Could You Do for Me One Day?: The 
Potential of the Genetic Information Nondiscrimination Act to Protect the American 
public, 21 WASH. U. J.L. & POL’Y 459, 464 (2006); Ellen Wright Clayton, Ethical, Legal, 
and Social Implications of Genome Medicine, 349 NEW ENG. J. MED. 562, 562 (2003). 
 39 Hudson et al., supra note 15, at 2662. 
 40 Id. at 2661. 
 41 Lauren Elizabeth Nuffort, Note, The Genetic Information 
Nondiscrimination Act of 2008: Raising a Shield to Genetic Discrimination in 
Employment and Health Insurance. 21 HEALTH L. 1, 10-11 (2009). 
 42 Patricia Alten, Note, GINA: A Genetic Information Nondiscrimination 
Solution in Search of a Problem, 61 FLA. L. REV. 379, 389 (2009); Nuffort, supra note 
41, at 11. 
 43 Hon. Louise McIntosh Slaughter, Genetic Testing and Discrimination: How 
Private is Your Information?, 17 STAN. L. & POL’Y REV. 67, 78 (2006); Nuffort, supra 
note 41, at 11. 
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decisions.44 These companies argued that access to such 
information allows them to both lower the potential costs 
associated with excessive sick leave as well as avoid the higher 
costs from potential increases in insurance claims from 
employees likely to become sick in the future.45 However, these 
arguments were refuted by a long history of discrimination in 
the workplace made possible by employers’ unregulated access 
to employees’ genetic information. As a result, Congress 
determined that despite the potential for increases in litigation 
and employer costs, GINA was an absolutely necessary law.46  
A. Genetic Discrimination of Racial and Ethnic Groups  
Long before the completion of the Human Genome 
Project and the resulting easy accessibility of genetic 
information, Americans still had reason to fear employment 
discrimination on the basis of their genes. In the early 1970s, 
scientists discovered a gene linked with sickle cell anemia—a 
blood disorder which is found in individuals of sub-Saharan 
African descent more commonly than other races.47 In response 
to this discovery, many states mandated sickle cell anemia 
screening for African-Americans.48 Later, researchers issued 
reports that those carrying the diseased gene might be more 
vulnerable to workplace toxins.49 While the mandatory testing 
policies were originally intended to merely identify carriers and 
thus offer prenatal testing, the results were not kept 
confidential and were ultimately used in a discriminatory 
manner.50 Healthy carriers of the gene suffered adverse 
employment actions, and a false stigma developed that African-
Americans were inherently more susceptible to genetic disease 
than individuals of other races.51 In 1972, Congress responded 
by passing the National Sickle Cell Anemia Control Act, which 
  
 44 Nuffort, supra note 41, at 11. 
 45 Id. 
 46 Daniel Schlein, New Frontiers for Genetic Privacy Law: The Genetic 
Information Nondiscrimination Act of 2008, 19 GEO. MASON U. CIV. RTS. L.J. 311, 351 
(2009). 
 47 Jungreis, supra note 1, at 228. 
 48 Christine Formas Norris, Note, The Genetic Information 
Nondiscrimination Act of 2008: History, Successes, and Future Considerations, 7 U. 
MD. L.J. RACE, RELIGION, GENDER & CLASS 192, 201 (2007). 
 49 Jungreis, supra note 1, at 228. 
 50 Id. at 228-29. 
 51 Norris, supra note 48, at 201. 
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banned states from federal funds unless their mandated sickle 
cell screening programs were made voluntary.52 
Like African-Americans, people of Ashkenazi (Eastern 
European) Jewish descent have also feared discriminatory 
treatment for their susceptibility as a group to certain genetic 
characteristics such as Tay-Sachs disease, as well as breast, 
colon, and ovarian cancers.53 As a result, in the 1980s, Rabbi 
Joseph Eckstein created an organization called Dor Yeshorim 
to prevent recessive genetic diseases from being passed from 
one generation to the next.54 This program screens Hasidic 
youths and informs them of their genetic compatibility with 
potential partners to prevent marriage and procreation among 
individuals possessing the genes for various diseases.55 In 
addition to preventing the tragedy of a child born with a life-
threatening genetic disorder, the program is also designed to 
“avoid the risk of stigmatizing . . . young single[s] . . . [and] 
their family members.”56 While this program may have sought 
to provide protection, in effect it has contributed to the 
stigmatization of individuals based on their genetic 
predispositions. 
B. Fears of Genetic Information in the Workplace—
Quantitative Evidence  
The most common concern among those who seek 
genetic testing is that the results will be used in some harmful 
way, typically either by denial of health insurance or by 
discrimination with regard to hiring or firing decisions.57 In 
1998, the federal government funded a national survey in 
conjunction with the National Center for Genome Resources to 
discern the public’s attitude regarding the emerging 
availability of genetic testing.58 Of the 1,000 people polled, 85% 
indicated that they did not want employers to have access to 
test results, and 27% answered that they would not be willing 
  
 52 Id. 
 53 Janet L. Dolgin, Personhood, Discrimination, and the New Genetics, 66 
BROOK. L. REV. 755, 789 (2001). 
 54 The Shidduch Site, Medical Issues (The Shidduch Site) Jewish Genetic 
Diseases, http://www.shidduchim.info/medical.html (last visited Jan. 16, 2010). 
 55 Slaughter, supra note 43, at 69. 
 56 The Shidduch Site, supra note 54. 
 57 Clayton, supra note 38, at 562. 
 58 Miller, supra note 22, at 232. 
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to take a genetic test if their employer could subsequently 
retrieve their results.59  
Although many people desire genetic testing for cancer, 
a large number clearly fear potential discrimination based on 
the outcome.60 In 1999, the Yale Cancer Center surveyed 300 
active cancer genetic counselors and found that 85% would test 
for the breast cancer gene mutation and 91% would test for the 
hereditary nonpolyposis colon cancer gene mutation.61 However, 
68% of those surveyed indicated that they would not submit the 
charges of these screenings to their healthcare providers, and 
26% claimed that they felt compelled to use a false name.62 
Similarly, the U.S. Department of Labor also discovered that 
many women do not partake in breast cancer screening due to 
a fear of stigmatization if the results are made available to 
their employers.63 
Recently, the American Management Association (the 
“Association”) has found that employers have engaged in 
discriminatory practices toward healthy employees found to be 
genetically predisposed to certain diseases.64 Importantly, the 
Association reported that employers have accessed their 
workers’ genetic information in the following ways: “one 
percent was conducting genetic tests for Sickle Cell Anemia, 
0.4 percent was testing for Huntington’s disease . . . [f]ourteen 
percent were conducting workplace susceptibility testing which 
surveyors acknowledged might include genetic testing, . . . [and 
t]wenty percent were requesting family medical histories.”65 In 
2007, the American Journal of Human Genetics reported that 
three-quarters of their survey respondents desired a federal 
law that would thwart employers from making hiring and 
  
 59 Id. at 232-33. A similar study was conducted by Georgetown University in 
1995. Researchers discovered there that “[w]orker’s fears of workplace 
discrimination . . . have prevented one out of ten respondents from getting tested for 
genetic traits linked to breast cancer, cystic fibrosis, Huntington’s Disease, colon 
cancer, or other conditions, even though early detection and treatment could possibly 
improve their lives.” Id. at 234.  
 60 Yale Cancer Center Study Underscores Fear of Discrimination Over Genetic 
Testing, SCI. DAILY, Oct. 25, 1999, http://www.sciencedaily.com/releases/1999/10/ 
991025075308.htm. 
 61 Id.  
 62 Id. In addition, “82% of counselors said that if tested positive, they would 
share the results with their physicians, but many would not want their carrier status 
documented in their medical records.” Id. 
 63 Miller, supra note 22, at 234. 
 64 Norris, supra note 48, at, 197-98. 
 65 Id. 
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firing decisions based on the respondents’ genetic likelihood of 
developing a disease in the future.66 
From these survey results, it is clear that fear of 
discrimination flowing from genetic testing hinders the use of 
screening technologies. Consequently, this fear has serious 
implications for the overall health and well-being of individuals 
who avoid genetic screening programs that could be beneficial 
to their health.67 In addition to individual concerns, the 
reluctance to utilize genetic testing raises serious social policy 
concerns. Most significantly, further scientific advancement 
relies on willing participants in clinical research.68 If people are 
unwilling to partake in genetic studies, this may hinder the 
development of new genetic tests and may even inhibit the 
discovery of new treatments for genetic diseases.69 This popular 
reluctance to genetic profiling creates difficulties for scientists 
who propose “massive population-based studies that will enable 
them to identify and distinguish genetic, environmental, and 
lifestyle-based contributors to disease.”70  
C. Judicial Application of Prior Legislation to Genetic 
Discrimination Cases 
Prior to the enactment of GINA, no federal law existed 
that specifically protected against workplace discrimination 
based on a genetic predisposition to certain diseases.71 Although 
minimal safeguards were given under the Americans with 
Disabilities Act and Title VII of the Civil Rights Act of 1964, 
these statutes were not extended to fully protect employees 
from discrimination based on their genetic profile.72 Further, 
some relief was made available to employees under federal 
privacy laws and via the Health Insurance Portability and 
Accountability Act of 1996.73 A presidential executive order and 
many state laws were also put in place to protect employees 
  
 66 Baruch & Hudson, supra note 9, at 437. 
 67 Kathy L. Hudson, Prohibiting Genetic Discrimination, 356 NEW ENG. J. 
MED. 2021, 2021-23 (2007). “At a recent congressional hearing, legislatures heard 
testimony about a woman who underwent testing for the BRCA1 gene, using a false 
name to keep her results private. Ovarian cancer later developed and her diagnosis 
was delayed because her genetic-test result was not in her medical record.” Id. 
 68 Norris, supra note 48, at 200. 
 69 Id. 
 70 Hudson, supra note 67, at 2021-23.  
 71 Sismondo, supra note 38, at 466. 
 72 Slaughter, supra note 43, at 72. 
 73 Miller, supra note 22, at 251-57. 
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from discrimination.74 But significant gaps remained, indicating 
that American workers needed additional protection through 
the use of uniform federal regulation.75 
1. Americans with Disabilities Act 
Prior to the passage of GINA, a worker experiencing 
genetic information discrimination usually sought relief under 
the Americans with Disabilities Act of 1990 (ADA). The ADA 
provides protection from employment discrimination for 
disabled employees that meet certain criteria.76 In order for an 
employee to make a successful case under the ADA, the 
employee must show that he or she is a “qualified individual 
with a disability.”77 The ADA defines a “qualified individual 
with a disability” as one who “with or without reasonable 
accommodation, can perform the essential functions of the 
employment position that such individual holds or desires.”78 
The recently amended ADA also provides the courts with 
guidelines for determining whether an employee is disabled, 
defining “disability” as a “physical or mental impairment that 
substantially limits one or more major life activities79 of such 
individual; a record of such impairment; or being regarded as 
having such an impairment.”80 
In addition, the ADA limits certain employers from 
requiring job candidates to provide medical information prior to 
the extension of a job offer.81 Once an offer of employment has 
  
 74 Id. at 248-251, 259-263. 
 75 Id. 
 76 Americans with Disabilities Act, 42 U.S.C. §§ 12101-12117 (2006). “No 
covered entity shall discriminate against a qualified individual with a disability 
because of the disability of such individual in regard to job application procedures, the 
hiring, advancement, or discharge of employees, employee compensation, job training, 
and other terms, conditions, and privileges of employment.” Id. § 12112(a). 
 77 Id. 
 78 Id. § 12111(8). 
 79 Id. § 12102(2). A “major life activity” includes but is not limited to “caring 
for oneself, performing manual tasks, seeing, hearing, eating, sleeping, walking, 
standing, lifting, bending, speaking, breathing, learning, reading, concentrating, 
thinking, communicating, and working.” ADA Amendments Act of 2008, Pub. L. No. 
110-325, 122 Stat. 3553, § 4(a)(3)(2)(A) (codified in scattered sections of 29 and 42 
U.S.C.). 
 80 ADA Amendments Act of 2008, § 4(a)(3). “An individual meets the 
requirement of ‘being regarded as having such an impairment’ if the individual 
establishes that he or she has been subjected to an action prohibited under this Act 
because of an actual or perceived physical or mental impairment whether or not the 
impairment limits or is perceived to limit a major life activity.” Id. § 4(a)(3)(A).  
 81 42 U.S.C. § 12112(d)(2)(A). 
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been given, however, the employer can require that the 
employee undergo a medical examination.82 If an employer 
requires such an exam, the requirement must apply to all job 
applicants equally, and the medical “inquiries must be job-
related and consistent with a business necessity.”83 
While the ADA will protect an employee who develops a 
genetically related illness when it begins to substantially limit 
a major life activity,84 this standard can be difficult to prove 
and, in many situations, plaintiffs with genetic disorders will 
not fit within the ADA provisions.85 For example, in Murphy v. 
United Parcel Service, the plaintiff suffered from hypertension, 
a condition which can be dependent both upon a person’s 
genetic makeup as well as the person’s lifestyle.86 The Court 
found that the plaintiff could not assert a claim under the ADA 
because he was not “regarded as” disabled; although the 
plaintiff was found to be unqualified to work in one particular 
job (as a mechanic),87 he was not substantially limited in the 
major life activity of working in a broad class of occupations.88 
In addition to difficulties of proof, the ADA does not 
address whether an employee’s genetic information, which 
indicates the likelihood of developing a future disease, can 
constitute a bona fide disability.89 To clarify the position of the 
federal government, the United States Equal Employment 
Opportunity Commission (“EEOC”) published guidelines 
indicating that the government’s interpretation of the ADA 
prohibits employment discrimination based on an individual’s 
  
 82 Id. § 12112(d)(3). 
 83 Jungreis, supra note 1, at 235 (citing 42 U.S.C. § 12112(d)(4)(A)). 
 84 Harris v. H & W Contracting Co., 102 F.3d 516, 524 (11th Cir. 1997). 
Plaintiff suffered from Graves’ Disease, an “endocrine disorder affecting the thyroid 
gland.” Id. at 517. Plaintiff suffered a panic attack and illness following an overdose of 
her medication. Id. at 518. The court held that this genetic disease is covered by the 
ADA. Id. at 524; see also Arnold v. United Parcel Service, Inc. 136 F.3d 854, 866 (1st 
Cir. 1998) (holding that a plaintiff may make out a discrimination claim under the 
ADA for diabetes mellitus). 
 85 Murphy v. United Parcel Service, Inc., 527 U.S. 516, 525 (1999). 
 86 Id. at 519. 
 87 Id. “A person with a genetic predisposition may demonstrate that they are 
substantially limited in the major life activity of working if the individual can prove 
that their employer mistakenly believes that, due to the genetic anomaly, they are 
unable to work in either a class of jobs or a broad range of jobs in various classes as 
compared to the average person.” Miller, supra note 22, at 246. 
 88 Murphy, 527 U.S. at 525. 
 89 Mark S. Dichter & Sarah E. Sutor, The New Genetic Age: Do Our Genes 
Make Us Disabled Individuals Under the Americans with Disabilities Act?, 42 VILL. L. 
REV. 613, 620 (1997). 
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genetic makeup.90 In particular, the EEOC’s guidelines argue 
that discrimination resulting from genetic testing is covered by 
the disability definition prong of the ADA because it constitutes 
“being regarded as having an impairment.”91 Along with the 
EEOC’s interpretive guidance, several court decisions suggest 
that an “employer’s concerns for an employee’s future 
productivity, health insurance costs, and attendance fall within 
the ‘regarded as’ prong of the ADA.”92 In its interpretative 
memoranda, the EEOC provides a hypothetical that describes 
an employer who retracts a job offer upon learning that the 
applicant is genetically predisposed to develop colon cancer in 
the future.93 Under this scenario, the EEOC argues that the 
candidate should receive anti-discrimination protection under 
the ADA.94 However, EEOC guidelines are merely persuasive 
and, in the past, the U.S. Supreme Court has not been swayed 
by the EEOC’s recommendations.95  
Although the Supreme Court has never ruled on the 
specific issue of whether the ADA protects an employee from 
discrimination if genetic testing indicates a predisposition for 
disease, the holding in Chevron U.S.A., Inc. v. Echazabal 
suggests that such information does not fall under the ADA’s 
disability provisions.96 In Echazabal, the employer refused to 
hire the plaintiff because the company’s required physical 
  
 90 See U.S. EEOC, COMPLIANCE MANUAL, § 902 (1995). 
 91 Id. 
 92 Miller, supra note 22, at 240; see Jones v. Inter-County Imaging Ctrs., 889 
F. Supp. 741, 742, 745 (S.D.N.Y. 1995) (denying defendant employer’s summary 
judgment motion to plaintiff’s ADA claim alleging that he was terminated because 
defendant believed that his sickle-cell condition would adversely affect future work 
attendance). The sickle cell trait originates through inheritance of an unstable 
hemoglobin variant (Hb S). HARRISON’S PRINCIPLES OF INTERNAL MEDICINE 1518 
(Anthony S. Fauci et al. eds., 17th ed. 2008). The abnormality occurs almost exclusively 
in persons of color. About eight percent of African-Americans are heterozygous for Hb 
S. Id. “Although the genetic abnormality may give rise to congenital hemolytic anemia, 
Hb S carriers generally have minimal clinical problems.” Miller, supra note 22, at 225 
n.121. 
 93 U.S. EEOC, supra note 90, § 902. 
 94 Id. 
 95 Sutton v. United Airlines, 527 U.S. 471, 482 (1999). The Supreme Court 
disagreed with the EEOC interpretation of the ADA that employees are to be evaluated 
in their “hypothetical uncorrected state,” and held that plaintiffs suffering correctible 
disabilities like vision impairment cannot make out a claim under the ADA. Id. The 
level of deference the Supreme Court will accord to EEOC guidelines “will depend upon 
the thoroughness evident in its consideration, the validity of its reasoning, its 
consistency with earlier and later pronouncements, and all those factors which give it 
power to persuade.” Gen. Elec. Co. v. Gilbert, 429 U.S. 125, 141-42 (1976). 
 96 Chevron U.S.A. Inc., v. Echazabal, 536 U.S. 73, 87 (2002); see Jungreis, 
supra note 1, at 238. 
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examination showed that the plaintiff had liver damage from 
Hepatitis C.97 The employer’s doctors said that the condition 
would be exacerbated by the exposure to toxins that were 
widespread at the employer’s refinery.98 Indeed, the employer 
“wish[ed] to avoid time lost to sickness, excessive turnover from 
medical retirement or death, litigation under state tort law, 
and the risk of violating the national Occupational Safety and 
Health Act of 1970.”99 To uphold the employer’s policy, the 
Court broadened its interpretation of the “direct threat to 
others” defense and allowed this type of testing to continue if it 
prevents threats to the health of individual employees.100 
Arguably, this expanded reading of defenses to an ADA claim 
could also allow genetic test results to be used in employment 
decisions.101  
The Seventh Circuit Court of Appeals has similarly 
indicated that the use of genetic information to withhold 
employment from applicants is permitted under the ADA.102 In 
EEOC v. Rockwell International, seventy-two job applicants 
were rejected by the employer based on their poor performance 
on nerve conduction tests administered as part of the 
application process.103 Although the applicants did not suffer an 
impairment at the time of the examination, the employer 
believed that the results of the tests indicated that these 
applicants were likely to develop carpal tunnel syndrome in the 
future.104 The court found that the ADA had not been violated 
since the job applicants were not currently disabled, nor were 
they mistakenly perceived to be currently disabled by the 
  
 97 Chevron, 536 U.S. at 76. 
 98 Id. 
 99 Id. at 84. 
 100 Id. at 78-79. 
 101 Jungreis, supra note 1, at 238. 
 102 EEOC v. Rockwell Int’l Corp., 243 F.3d 1012, 1017 (7th Cir. 2001). 
 103 Id. at 1014. 
 104 Id. In Rockwell, the employer described the genetic testing as follows: 
The tests were designed . . . to confirm the presence of neuropathy—a 
syndrome characterized by, among other things, sensory loss and muscle 
weakness. . . . Rockwell sent each applicant to a medical facility where the 
median nerves in his or her arms were stimulated with electric shocks and 
the travel time of the electrical impulse from the shock points to the muscles 
was recorded. The results of the test were given to Rockwell, which used 
them in making personnel decisions. 
Id. 
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employer.105 Consequently, this case indicates a likelihood that 
courts will not be afraid to dismiss discrimination claims 
brought under the ADA when employers use genetic 
information to predict the future health of job applicants. 
In contrast to Echazabal and Rockwell, Bragdon v. 
Abbott suggests the possibility that the ADA could afford 
protection from discrimination based upon genetic 
predispositions for diseases.106 In Bragdon, the Supreme Court 
found that the plaintiff’s HIV infection, though asymptomatic, 
substantially limited the major life activity of reproduction 
because it would impose a serious risk of infection to her sexual 
partner and her future offspring.107 Miller notes that 
“asymptomatic HIV is a physical impairment from the moment 
of infection due to ‘the immediacy with which the virus begins 
to damage the infected person’s blood cells and the severity of 
the disease.’”108 While the Court recognized that an individual 
infected with HIV remained capable of reproduction, 
reproduction was regarded as dangerous to the public health, 
and “[w]hen significant limitations result from the impairment, 
the definition [of disability] is met even if the difficulties are 
not insurmountable.”109 
A parallel can be drawn between individuals with a 
presently asymptomatic condition that will eventually progress 
to a serious deterioration of the immune system and those who 
are predisposed to a genetic disorder but currently show no 
evidence of the disease.110 The latter are therefore also arguably 
  
 105 Id. at 1012. In a similar case decided that same year, the EEOC chose to 
settle. EEOC v. Burlington N. Santa Fe R.R., No. 02-C-0456, 2002 WL 32155386, at *1 
(E.D. Wis. May 8, 2002) (Agreed Order). Here the employer was also testing for a 
genetic condition that causes carpal tunnel syndrome. Id. The employer “additionally 
threatened one employee with termination when they refused to comply. According to 
the EEOC, the genetic tests were unlawful under the ADA because they were not job-
related, and conditioning employment on genetic test results constituted disability 
discrimination.” Norris, supra note 48, at 203-04.  
 106 See Bragdon v. Abbott, 524 U.S. 624, 644-45 (1998). 
 107 Id. at 639-40. 
 108 Miller, supra note 22, at 242 (quoting Bragdon, 524 U.S. at 637).  
 109 Bragdon, 524 U.S. at 641.  
 110 Miller, supra note 22, at 243. Miller noted: 
Science may be able to demonstrate that many asymptomatic genetic 
disorders, while not resulting in any visible symptoms or characteristics, may 
create abnormalities in an individual’s body systems or changes on a cellular 
level as was shown with asymptomatic HIV. . . . Should a plaintiff be able to 
demonstrate that the genetic condition causes some abnormality in the 
person’s body, even on a molecular level, the condition would constitute a 
physical impairment for ADA purposes. 
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protected by the ADA under Bragdon. In addition, it could be 
argued that some genetic predispositions, although 
asymptomatic, limit a major life activity, as seen in Bragdon.111 
However, there is clearly disagreement and a lack of clarity 
between the outcome of Bragdon and the reasoning applied in 
cases such as Chevron, Murphy, and Rockwell.112 As a result, 
federal legislation separate from the ADA that specifically 
addressed the growing field of genetic testing was necessary to 
provide adequate protection for employees in the workplace. As 
a practical matter, it had also been extremely difficult for 
plaintiffs to win ADA cases.113 In 1999, the American Bar 
Association Commission on Mental and Physical Disability 
Law reported that defendant employers won 291 cases in the 
federal court system, while only 13 plaintiff employees 
prevailed.114 Consequently, GINA was a necessary reform to 
give employees a chance to fight genetic information 
discrimination in the workplace.  
2. Title VII of the Civil Rights Act of 1964 
Like the ADA, Title VII of the Civil Rights Act of 1964 
(“Title VII”) provides minimal relief to those suffering adverse 
employment actions because of their predisposition to genetic 
disease.115 Title VII is limited to barring employment 
discrimination on the basis of race, color, religion, sex, or 
national origin.116 While several genetic diseases do correlate 
with race, sex, and national origin, they are not solely 
dependent upon these characteristics.117  
Under Title VII, employees can prevail on a claim if 
they establish that the employer singled out a specific 
  
Id. at 243-44. 
 111 See Bragdon, 524 U.S. at 637. 
 112 See Chevron U.S.A. Inc. v. Echazabel, 536 U.S. 73 (2002); Murphy v. 
United Parcel Serv., Inc., 527 U.S. 516 (1999); EEOC v. Rockwell, 243 F.3d 1012 (7th 
Cir. 2001). 
 113 Marisa Anne Pagnattaro, Genetic Discrimination and the Workplace: 
Employee’s Right to Privacy v. Employer’s Need to Know, 39 AM. BUS. L.J. 139, 165 
(2001).  
 114 Id.; see also Claudia MacLachlan, Employers Winning ADA Suits: ABA 
Study Shows Employees Won Only 13 Cases in 1999, NAT’L L.J., July 31, 2000. “That 
means that ‘employers won 95.7% of the time,’ an increase over the 1998 survey 
results.” Id. 
 115 Jungreis, supra note 1, at 239. 
 116 42 U.S.C. § 2000e-2(a) (2006). 
 117 Jungreis, supra note 1, at 239. 
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protected class for genetic testing.118 In Norman-Bloodsaw v. 
Lawrence Berkely Laboratory, the employer forced its black 
female employees to undergo genetic testing for sickle cell 
anemia, syphilis, and pregnancy.119 In that case, the plaintiffs’ 
claims were deemed valid because the court found 
discrimination based on race and sex, both protected classes 
under Title VII.120  
However, if all employees of the lab had been required 
to undergo genetic testing, there would not have been a 
successful Title VII disparate treatment claim since each 
employee would have been treated equally.121 A disparate 
impact claim might be possible if, for example, a 
disproportionate number of black employees tested positive for 
sickle cell anemia and then suffered adverse employment 
actions.122 However, it is clear that Title VII can only be applied 
to genetic information discrimination under a very narrow set 
of circumstances.123 As with the ADA, the scant coverage 
provided by Title VII indicated to Congress the need for 
separate federal legislation that would specifically target 
employment discrimination on the basis of genetic 
predisposition to disease. 
3. Executive Order on Genetic Discrimination 
Based on the inability of the ADA and Title VII to 
provide employees with protection from discrimination on the 
basis of their genetic information, President Clinton saw a need 
for increased safeguards against discriminatory behavior in the 
workplace.124 On February 8, 2000, he issued Executive Order 
13,145, To Prohibit Discrimination in Federal Employment 
Based on Genetic Information (the “Executive Order”).125 The 
  
 118 Norman-Bloodsaw v. Lawrence Berkely Lab., 135 F.3d 1260, 1272 (9th Cir. 
1998). 
 119 Id. at 1265. 
 120 Id. at 1272. 
 121 See generally ROBERT BELTON ET AL., EMPLOYMENT DISCRIMINATION LAW: 
CASES AND MATERIALS ON EQUALITY IN THE WORKPLACE ch. 4 (7th ed. 2004). 
 122 See generally id. 
 123 See generally id. 
 124 Miller, supra note 22, at 248. 
 125 Exec. Order No. 13,145, 65 Fed. Reg. 6,875 (Feb. 8, 2000) [hereinafter 
Exec. Order No. 13,145], available at http://eeoc.gov/eeoc/history/35th/thelaw/ 
13145.html. The purpose of this Order is as follows: 
Executive Order 13145 is intended to ensure that Executive branch 
applicants and employees are judged on their current ability to perform the 
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Executive Order targeted departments and agencies of the 
federal government by limiting their access to, and use of, their 
employees’ genetic information. 
The Executive Order prohibits federal departments and 
agencies from taking adverse employment actions based on an 
employee’s “protected genetic information.”126 This “protected 
genetic information” is defined in the Executive Order as “(1) 
information about an individual’s genetic tests; (2) information 
about the genetic tests of an individual’s family members; or (3) 
information about the occurrence of a disease, or medical 
condition or disorder in family members of the individual.”127 
The Executive Order makes clear that the federal government 
is barred from making employment decisions based upon a 
worker’s predisposition to disease, medical condition, or other 
physical disorder that does not impact his or her ability to 
currently carry out the responsibilities of the position.128 
Likewise, under the Executive Order, federal employers are 
also prohibited from mandating genetic tests as a condition of 
employment,129 including hiring and receiving benefits, 
evaluating ability to perform the job, and classifying employees 
in a discriminatory manner leading to lost job advancement 
opportunities.130 
In most instances, the Executive Order demands that 
genetic information be kept confidential and removed from 
  
jobs they seek or hold, and not on the possibility that they might, some day, 
develop a disease or condition. Accordingly, the Executive Order places 
stringent limits on the collection, use, and disclosure of protected genetic 
information. 
U.S. EEOC, POLICY GUIDANCE ON EXECUTIVE ORDER 13145: TO PROHIBIT 
DISCRIMINATION IN FEDERAL EMPLOYMENT BASED ON GENETIC INFORMATION, 
http://www.eeoc.gov/policy/docs/guidance-genetic.html. 
 126 Exec. Order No. 13,145, supra note 125, at 6877. 
 127 Id. “Information about an ‘individual’s current health status (including 
information about sex, age, physical exams, and chemical, blood, or urine analyses) is 
not protected genetic information’ unless it falls within one of the above categories.” 
Pagnattaro, supra note 113, at 157. 
 128 Exec. Order No. 13,145, supra note 125, at 6877. 
 129 Id. 
 130 Id. Disclosure of such information is warranted only in the following 
circumstances: 
(1) to the employee; (2) to a person conducting research that complies with 45 
C.F.R. Part 46, which concerns research involving human subjects; (3) if 
required by federal law; (4) in response to a congressional subpoena or order 
from a court with competent jurisdiction; or (5) to Executive branch officials 
investigating compliance with the Executive Order. 
Id. 
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personnel files that can be easily accessed. However, the 
Executive Order does provide federal employers some leeway to 
require family medical information from prospective employees 
who have already received conditional employment offers.131 
Such information is only to be used for the purpose of 
determining whether an applicant needs additional testing to 
diagnose an existing disease or health condition that could 
prevent the individual from fulfilling his or her current job 
responsibilities.132 The results of these tests may only be viewed 
by medical personnel in charge of assessing whether the 
applicant must undergo additional medical testing.133 
Although the Executive Order expands the rights of 
federal employees beyond the ADA and Title VII, it leaves out 
the large number of Americans who are not employed by the 
federal government. Therefore, the vast majority of Americans 
still required legislation that prevented private employers from 
using their employees’ genetic information as a means for 
discriminatory behavior. 
4. Constitutional Privacy Rights and the Privacy Act of 
1974 
Another source of potential protection against genetic 
discrimination in the workplace is the Fourteenth Amendment 
of the U.S. Constitution. Indeed, some courts have held that an 
individual has the right to keep personal health information 
private and, therefore, employees should be protected against 
genetic information discrimination under the Fourteenth 
Amendment.134 For example, in United States v. Westinghouse 
Electric Corp., the Third Circuit Court of Appeals stated that 
there is “no question that an employee’s medical records, which 
may contain intimate facts of a personal nature, are well 
within the ambit of materials entitled to privacy protection.”135 
The court held that “[g]enetic information should thus be 
protected pursuant to the right to privacy under the United 
States Constitution.”136  
  
 131 Id. 
 132 Id. 
 133 Id. at 6879. 
 134 This applies only to state actors (government employers). Miller, supra 
note 22, at 251. 
 135 U.S. v. Westinghouse Elec. Corp., 638 F.2d 570, 577 (3d Cir. 1980). 
 136 Miller, supra note 22, at 251.  
564 BROOKLYN LAW REVIEW [Vol. 75:2 
 
Similarly, the Supreme Court has found that, in certain 
situations, the government does have an obligation under the 
Fourteenth Amendment to avoid disclosing private 
information.137 However, the Court has provided little guidance 
as to when such situations will arise. In Whalen v. Roe, 
patients requiring Schedule II drugs (the most dangerous of 
legitimate prescription medications) declined treatment due to 
their concern that the computerized records would stigmatize 
them as drug addicts.138 Furthermore, doctors worried that they 
could not adequately treat their patients without privacy 
protection for their records.139 While the Court was “not 
unaware of the threat to privacy implicit in the accumulation of 
vast amounts of personal information in computerized data 
banks,” it did not find a violation of “any right or liberty 
guaranteed” by the Fourteenth Amendment.140  
More pointedly, the Ninth Circuit Court of Appeals 
specifically addressed the issue of whether privacy rights apply 
to genetic information in Norman-Bloodsaw v. Lawrence 
Berkeley Laboratory.141 In Norman-Bloodsaw, the employer 
conducted genetic testing for syphilis, pregnancy, and sickle 
cell anemia during routine mandatory medical exams, but 
without the authorization of the employees.142 The plaintiffs 
challenged these practices as violations of both the ADA and 
Title VII and alleged that under the U.S. Constitution, their 
rights to privacy and due process had been denied.143 The court 
determined that administering genetic tests without the 
consent of an employee was a clear violation of that employee’s 
right to privacy.144 In addition, the court found that “the 
  
 137 Whalen v. Roe, 429 U.S. 589, 605 (1977). 
 138 Id. at 595.  
 139 Id. at 604. 
 140 Id. at 605-06.  
 141 Norman-Bloodsaw v. Lawrence Berkeley Lab., 135 F.3d 1260, 1269 (9th 
Cir. 1998). 
 142 Id. at 1264-65. 
 143 Id. at 1265. While granting relief on the constitutional claims, the court 
“dismiss[ed] . . . the ADA claims on the following grounds: (1) that no job related action 
was taken against the plaintiffs as a result of the testing; (2) the lack of evidence of 
inadequate safeguards to protect the confidentiality of the information; and (3) the 
scope of exams did not violate the statute.” Miller, supra note 22, at 253. For a 
discussion of the outcome of the Title VII claims see supra Part II(C)(2).  
 144 Miller, supra note 22, at 253; see Norman-Bloodsaw, 135 F.3d at 1269. 
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performance of these tests, without explicit notice and informed 
consent, violates prevailing medical standards.”145 
Even if the Supreme Court eventually holds that genetic 
information testing requires protection under the Fourteenth 
Amendment, federal constitutional privacy interests can still 
be challenged. Under this analysis, privacy rights “must be 
balanced against the [federal and/or state] government 
employer’s legitimate interest in collecting the information.”146 
Thus, if a government employer can put forth a valid reason for 
requiring genetic information from their employees, the courts 
will not infringe upon these practices, even if they result in 
discriminatory behavior.147 
An additional modicum of protection for employees may 
be found in the Privacy Act of 1974 (the “Privacy Act”).148 The 
Privacy Act regulates the collection and use of records by 
federal agencies and limits their access to information 
“relevant and necessary” to their purpose.149 Under the Privacy 
Act, one is allowed to access his or her personal records on 
request and seek amendment to his or her file if it is 
inaccurate.150 Finally, the Act limits disclosure of records to 
outside parties.151  
The holdings of Whalen and Norman-Bloodsaw suggest 
that the Supreme Court is likely to find, in some situations, 
that employees’ genetic test results should be shielded from an 
employer.152 In these limited situations, employees would be 
protected from discrimination since their employer would not 
have access to genetic information indicating that they are 
predisposed to develop a disease in the future.153 However, these 
rights can be limited if the government employer can show a 
legitimate interest in obtaining the information.154 
  
 145 Miller, supra note 22, at 253 (internal quotation marks omitted) (quoting 
Norman-Bloodsaw, 135 F.3d at 1267). 
 146 Id. at 251. 
 147 Id. at 253. 
 148 5 U.S.C. § 552(a) (2006). “Like the federal Constitution, however, it applies 
to only government action, particularly, the disclosure of information obtained by a 
government agency.” Miller, supra note 22, at 253; see Norman-Bloodsaw, 135 F.3d at 
1269. 
 149 Miller, supra note 22, at 253 (citation omitted) (internal quotation marks 
omitted). 
 150 Id. at 253-54. 
 151 Id. at 254. 
 152 Norman-Bloodsaw, 135 F.3d at 1269.  
 153 Miller, supra note 22, at 253. 
 154 Id. 
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Furthermore, since these protections only apply to federal 
employees, those working in the private sector will be barred 
from making similar claims.155 Consequently, GINA was 
required to provide a litigation outlet for the majority of 
employees. 
5. The Health Insurance Portability and Accountability Act 
Limited protection from genetic discrimination in health 
insurance access is also provided by the Health Insurance 
Portability and Accountability Act of 1996.156 However, like the 
legislation previously discussed, HIPAA does not provide 
sufficient protection against genetic discrimination in the 
workplace. Since many Americans participate in group health 
insurance through their employers, HIPAA has become 
intertwined with workers’ rights issues.157 HIPAA bars group 
health insurance plans from abusing their access to 
participants’ genetic information to deny continued eligibility 
in the plan.158 In most cases, HIPAA enables individuals to 
receive insurance coverage even if they have prior or current 
medical conditions and it allows employees to retain coverage if 
they switch jobs or insurance providers.159 Most significantly, 
under HIPPA, genetic information alone cannot constitute a 
preexisting condition or a means for excluding a covered 
employee.160 Therefore, a member of a group health insurance 
plan who discovers that he has a gene that may predispose him 
to a disease will not be denied coverage if the plan is covered by 
HIPAA.161 
Although HIPAA took the first steps toward directly 
targeting genetic discrimination, the statute is not sufficient.162 
While HIPAA prevents health care providers from increasing 
the cost of an individual’s insurance in a discriminatory 
manner, insurance companies are not barred from raising an 
  
 155 Id. 
 156 29 U.S.C. § 1181 (2006). 
 157 Miller, supra note 22, at 255. 
 158 29 U.S.C. § 1181(d)(1). 
 159 Miller, supra note 22, at 255.  
 160 Id. 
 161 Miller, supra note 22, at 255. “In addition, coverage cannot be denied for a 
newborn or newly adopted child’s medical condition, as long as the child is enrolled 
within thirty days of birth or adoption, and benefits for the medical condition are 
otherwise available under the plan.” Id. 
 162 Norris, supra note 48, at 204-05. 
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employer’s group premium based on the genetic makeup of its 
employees.163 Furthermore, HIPAA does not apply to 
individuals or the self-employed seeking health insurance 
independently; nor does it prohibit health care providers from 
denying coverage to these individuals outright.164 This gap in 
HIPAA affects approximately 10-15% of people who purchase 
health insurance individually.165 Finally, even though HIPAA 
bars insurers from rescinding policies to a small employer due 
to the genetic information of an enrollee, the same rule does 
not apply to larger employers.166 
Like prior attempts at regulation, the gaps in HIPAA, 
which allow for genetic information discrimination to occur, 
indicate that specific reform was needed to provide protection 
to employees.  
6. State Law Protecting Against the Misuse of Genetic 
Information by Employers 
The abuse of genetic information in employment was 
first addressed by state legislatures in the 1970s and 1980s 
through the creation of protective provisions for workers with 
the genetic marker for sickle cell anemia.167 Some of the first 
states to enact such statutes were Florida, Louisiana, and 
North Carolina.168 In 1981, New Jersey followed suit and 
banned employment discrimination based on a worker’s genetic 
predisposition for “sickle cell anemia, hemoglobin C, 
thalassemia, Tay Sachs, or cystic fibrosis.”169 Currently, thirty-
four states and the District of Columbia have enacted 
legislation barring genetic discrimination in decisions 
regarding hiring, firing, and/or determining the terms, 
conditions or privileges of employment.170 However, there is 
great variation in the scope and application of these laws. For 
those that provide some level of protection for employees, 
  
 163 Id. at 205. 
 164 See 29 U.S.C. § 1181. 
 165 Norris, supra note 48, at 205. 
 166 Id. 
 167 NAT’L CONFERENCE OF STATE LEGISLATURES, GENETIC EMPLOYMENT LAWS 
(2008) [hereinafter NAT’L CONFERENCE], available at http://www.ncsl.org/ 
IssuesResearch/Health/GeneticEmploymentLaws/tabid/14280/Default.aspx. 
 168 Id. 
 169 Mark A. Rothstein, Is GINA Worth the Wait?, 36 J.L. MED. & ETHICS 174, 
175 (2008). 
 170 NAT’L CONFERENCE, supra note 167. 
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twenty-five states prohibit employers from requiring genetic 
testing, eighteen prohibit employers from requesting genetic 
test results, and sixteen prohibit employers from performing 
their own genetic testing in the workplace.171 Only eleven states 
outright ban employers from obtaining the genetic test results 
of their workers.172 
While it now appears that protections provided by states 
are on the rise, prior to the enactment of GINA, residents of 
fifteen states were left with only the bare-bones federal 
protection discussed earlier. Moreover, a system reliant solely 
on state law has proven difficult to administer since the 
various protections offered by each state unnecessarily burden 
multi-state employers with a grab-bag of state rules and 
regulations.173 Furthermore, prior to uniform federal regulation, 
employees continued to fear genetic testing despite local 
protections.174 If workers chose to relocate to a state that lacked 
similar legislation regarding genetic information, it would be 
too risky to have potentially harmful information in their 
medical records.175 
III. NEW PROTECTIONS PROVIDED BY GINA 
After almost thirteen years of consideration by 
Congress, GINA passed, filling in the gaps in federal law and 
providing protection to the American workforce.176 On May 21, 
2008, President George W. Bush signed GINA into law,177 and it 
went into effect on November 21, 2009.178 As the first civil rights 
legislation of the twenty-first century,179 “GINA represents 
significant progress in protecting civilians from genetic 
discrimination in employment and health insurance.”180 
  
 171 Id. 
 172 Id. In addition, only fourteen states have created specific penalties for 
genetic discrimination in employment. Id. 
 173 Jungreis, supra note 1, at 233. 
 174 Id. 
 175 Id. 
 176 Baruch & Hudson, supra note 9, at 435. 
 177 Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 
122 Stat. 881. 
 178 Id. § 213. 
 179 Hudson et al., supra note 15, at 2662. 
 180 Baruch & Hudson, supra note 9, at 437. “[W]hen it finally overcame the 
opposition of a few members of Congress who controlled the rules of the House and 
Senate for many years, it passed almost unanimously, with strong bipartisan support.” 
Id. at 435. 
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Significantly, GINA was drafted to target both 
employers and health care providers. Title I targets genetic 
information discrimination in health insurance benefits and 
group health plans.181 In particular, it “prohibits the use of 
genetic information to set health insurance premiums, deny 
coverage, or affect employment.”182 More specifically, GINA 
“prohibits group and individual health insurers from using a 
person’s genetic information in determining eligibility or 
premiums; prohibits an insurer from requesting or requiring 
that a person undergo a genetic test; and prohibits employers 
from using a person’s genetic information about persons or 
their family members.”183 Title I applies to all ERISA group 
health plans, group market insurers, individual market 
insurers, Medicare supplemental insurers, and non-federal 
governmental plans.184 
Title II of the Act applies specifically to genetic 
discrimination in employment.185 This title pertains to 
employers, employment agencies, and labor organizations.186 
Under GINA, it is unlawful for employers to make hiring and 
firing decisions based on employees’ genetic information.187 
Furthermore, the statute prohibits employers from using 
genetic information to take discriminatory actions regarding 
compensation, benefits, or other terms and conditions of 
employment.188 In addition, an employer is also barred from 
segregating or classifying employees in a manner that would 
deprive them of employment opportunities or adversely affect 
their employment status because of genetic data.189 
In addition to proscribing genetic discrimination, GINA 
also prohibits employers from requesting, requiring, or 
purchasing genetic information of an employee or from family 
members of the employee.190 However, the Act does provide six 
  
 181 GINA, H.R. 493, 110th Cong. (2008). 
 182 Allison, supra note 7, at 596. 
 183 Hudson et al., supra note 15, at 2662. 
 184 Nuffort, supra note 41, at 12. 
 185 GINA, H.R. 493. 
 186 GINA, § 201(a)(2)(B); id. § 201(C). “Covered employees” (including an 
applicant) are those defined in section 701(f) of the Civil Rights Act of 1964 (42 U.S.C. 
§ 2000e(f)). Id. 
 187 Id. § 202(a)(1). 
 188 Id. 
 189 Id. § 202(a)(2). 
 190 Id. § 202(b).  
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exceptions to this rule.191 First, there is no unlawful 
employment practice when an employer makes an inadvertent 
mistake requesting family medical history.192 Likewise, there is 
also no violation when an employee provides voluntary, written 
authorization for employers to obtain family genetic 
information.193 In addition, employers may request family 
medical information in order to comply with the Family 
Medical Leave Act of 1993 or similar state laws.194 Employers 
may also purchase commercially and publically available 
documents that contain family medical information of an 
employee.195 An employer may also require genetic information 
if it is to be used for genetic monitoring of the biological effects 
of toxic substances in the workplace.196 To fall within this 
exemption, the employer must provide written notice to the 
employee, obtain voluntary and written authorization from the 
employee, and keep the employee informed of individual 
monitoring results.197 Such monitoring must also be required by 
Federal or State law, and must be in compliance with the 
Occupational Safety and Health Act of 1970.198 Lastly, the 
genetic monitoring results must be received in the aggregate 
and cannot identify individual employees.199 Finally, GINA also 
provides an exception when an employer must conduct DNA 
analysis for law enforcement purposes or when it is necessary 
to identify human remains.200 
GINA provides definitions for key terms such as 
“genetic information,” “genetic services,” and “genetic test.”201 
  
 191 Id. § 202(b)(1)-(6). 
 192 Id. § 202(b)(1). 
 193 Id. § 202(b)(2). 
 194 Id. § 202(b)(3). 
 195 Id. § 202(b)(4). Employers may consult newspapers, magazines, periodicals, 
and books, but cannot use medical databases or court documents to obtain genetic 
information of an employee.  
 196 Id. § 202(b)(5). 
 197 Id. § 202(b)(5)(A); id. § 202(b)(5)(B)(i); id. § 202(b)(5)(C). 
 198 Id. § 202(b)(5)(B)(ii); id. § 202(b)(5)(D). 
 199 Id. § 202(b)(5)(E). 
 200 Id. § 202(b)(6). 
 201 Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 
122 Stat. 881. “Genetic information” is: 
information about genetic tests, the genetic tests of family members, and the 
manifestation of a disease or disorder in family members (a ‘family member’ 
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includes any request for, or receipt of, genetic services, or participation in 
clinical research that includes genetic services, by an individual or his or her 
family members. ‘Genetic services’ may include a genetic test, genetic 
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Examples of genetic tests that will now be protected under 
GINA include, but are not limited to, the following: “tests for 
BRCA1/ BRCA2 (breast cancer) or HNPCC (colon cancer) 
mutations; classifications of genetic properties of an existing 
tumor to help determine therapy; tests for Huntington disease 
mutations; carrier screenings for disorders such as cystic 
fibrosis, sickle cell anemia, spinal muscular atrophy, and the 
fragile X syndrome.”202 
Several federal agencies have been charged to enforce 
GINA, including the Department of Health and Human 
Services, the Department of Labor, and the Department of 
Treasury, along with the EEOC.203 In addition, GINA mandates 
that a Genetic Nondiscrimination Study Commission be formed 
by May 2015.204 This new Commission will review scientific 
advancements in genetics and advise Congress as to the 
potential need to amend GINA to include disparate impact 
causes of action.205 The Commission will be comprised of eight 
members and will be located in a facility within the EEOC.206 
During deliberations, members of Congress determined 
that the imposition of harsher penalties for violations of GINA 
would be illogical and unreasonable if they exceeded the 
  
counseling (including obtaining, interpreting, or assessing genetic 
information), or genetic education. The law states specifically that genetic 
information does not include information about sex or age. Further 
clarification about the scope of these definitions is expected through the 
federal regulatory process, currently under way. The definition of ‘genetic 
test’ is quite specific. Under GINA, genetic test means an analysis of human 
DNA, RNA, chromosomes, proteins, or metabolites to detect genotypes, 
mutations, or chromosomal changes. However, according to the law, genetic 
test does not include ‘(i) an analysis of proteins or metabolites that does not 
detect genotypes, mutations, or chromosomal changes; or (ii) an analysis of 
proteins or metabolites that is directly related to a manifested disease, 
disorder, or pathological condition that could reasonably be detected by a 
healthcare professional with appropriate training and expertise in the field of 
medicine involved. It is important to note that (ii) does not appear in the 
employment section of the law- in the workplace, this exception to the 
definition of genetic test would not apply. In other words, GINA does not 
prohibit insurers from underwriting based on information that reveals 
information about current health status. However, employers may not use 
such information to make employment decisions. 
Baruch & Hudson, supra note 9, at 438-39; Genetic Information Nondiscrimination Act 
of 2008, Pub. L. No. 110-233, 122 Stat. 881. 
 202 Genetics & Pub. Policy Ctr., John Hopkins Univ., Information on the 
Genetic Information Nondiscrimination Act (GINA) [hereinafter Information on GINA], 
www.DNApolicy.org. 
 203 Baruch & Hudson, supra note 9, at 439. 
 204 GINA, § 208(b). 
 205 Id. 
 206 Id. § 208(c). (d). 
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penalties for violating other employment laws such as the 
ADA, Title VII, and HIPPA.207 It was felt that consistency would 
ensure the bill’s passage and avoid overloading the burden on 
health insurers and employers.208 However, remedies such as 
corrective action and monetary awards are available to harmed 
employees.209 In addition, citizens of states that have more 
encompassing protection under state law than under GINA will 
still be able to bring state law claims if they suffer genetic 
discrimination in the workplace.210 
With GINA in effect, workers who suffer from adverse 
employment action based on their employer’s knowledge of 
their genetic predisposition to develop a disease will have a 
claim and remedy under federal law.211 Significantly, plaintiff 
employees no longer have to stretch the facts of their case to fit 
within the regulatory framework of the ADA and Title VII, 
which offer inadequate protection for genetic information 
discrimination.212  
IV. WHAT GINA LEFT OUT AND THE PROTECTIONS 
REQUIRED IN THE FUTURE 
Despite the clear advantages that GINA provides to 
employees seeking relief from genetic information 
discrimination in the workplace, the Act fails to provide 
comprehensive protection. On the one hand, some remaining 
gaps in the legislation are due to the fact that GINA sponsors 
needed to make compromises for it to be passed.213 Other 
weaknesses in the act are due to the rapid advancement of 
clinical medicine and biotechnology.214 
Critics of GINA argue that the act is too narrow and 
limited in scope.215 For them, the Act “does not prevent health 
  
 207 Baruch & Hudson, supra note 9, at 439. See generally IOMA, supra note 
16. 
 208 Baruch & Hudson, supra note 9, at 439. 
 209 Employer Advocates, supra note 16, at 1-6. 
 210 Baruch & Hudson, supra note 9, at 439. 
 211 Id. 
 212 See supra Part II.(A), (B). 
 213 Baruch & Hudson, supra note 9, at 435. “GINA is, like most enacted laws, 
a compromise and reflects a strategic and delicate balancing of interests of all key 
stakeholders including providers, patients, insurers, employers, researchers, and 
lawmakers.” Id.  
 214 J. M. Appel, When the Boss Turns Pusher: A Proposal for Employee 
Protections in the Age of Cosmetic Neurology, 34 J. MED. ETHICS 616, 618 (2008). 
 215 Baruch & Hudson, supra note 9, at 435.  
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care providers from recommending genetic tests to their 
patients . . . , mandate coverage for any particular test or 
treatment . . . , prohibit medical underwriting based on current 
health status . . . , cover life, disability or long-term-care 
insurance, [and does not] apply to members of the military.”216 
With regard to employment issues in particular, GINA “does 
not prohibit workplace collection of genetic information for 
toxicity monitoring programs, employer-sponsored wellness 
programs, administration of federal and state Family and 
Medical Leave laws, and in certain cases of inadvertent 
acquisition of information.”217 
In the near future, courts may have to determine 
whether employers can require DNA testing for criminal 
background checks under GINA. Recently, the University of 
Akron implemented a policy reserving the right “to require any 
prospective faculty, staff, or contractor to submit a DNA 
sample.”218 While employers typically conduct general 
background checks during the hiring process, the Ohio school is 
the first to take such extreme measures.219 The school 
maintains that Akron’s goal is solely to sustain a safe 
environment for students and staff and that “DNA testing was 
included in the policy because there ha[s] been national 
discussion that indicate[s] that in the future, reliance on 
fingerprinting will diminish and DNA for criminal 
identification will be the prominent technology.”220 Arguably, 
GINA does not delineate a distinction between requiring 
genetic information for discriminatory versus legitimate 
purposes; likewise, the policy is not covered by one of the 
exceptions mentioned above.221 Since one employee has already 
quit in response to the school’s policy,222 this may lead to the 
first opportunity for the courts to evaluate GINA’s reach.  
GINA also fails to protect those who suffer from other 
immutable characteristics that may indicate a likelihood of 
developing an illness in the future, such as abnormalities found 
  
 216 Hudson et al., supra note 15, at 2662. 
 217 Information on GINA, supra note 202. 
 218 Declan McCullagh, Want a Job in Akron? Hand Over Your DNA, CBS 
NEWS, Oct. 28, 2009, http://www.cbsnews.com/blogs/2009/10/28/taking_liberties/ 
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on a screening colonoscopy.223 Thus, an insurance company can 
implement discriminatory coverage and pricing policies against 
these individuals, even though it could not do so to persons 
with a genetic predisposition for the condition.224  
For many employees who believe that they should now 
be protected, GINA stands to cause confusion since many 
medical tests and examinations are not covered by the act.225 
Routine screenings “such as complete blood counts (CBC, or 
blood panel), cholesterol tests, and liver-function tests are not 
protected under GINA.”226 This is problematic since cholesterol 
levels, for example, can depend on a person’s genetic makeup 
and thus cannot always be controlled by lifestyle choices.227 As a 
potentially immutable characteristic, these patients should also 
receive some form of protection against employer 
discrimination. Other areas of concern include: “DNA analysis 
of infectious agents such as bacteria, viruses, and fungi. An 
HIV test, for example, is not covered. Although it is a 
retrovirus that inserts itself into human DNA, HIV is not itself 
human DNA and measuring its presence does not constitute a 
genetic test under the law’s definition.”228 From these examples, 
it is clear that there is a fuzzy line as to what constitutes a 
genetic test. Arguably, GINA’s reach is too narrow and should 
be expanded to encompass additional borderline traits such as 
cholesterol.  
  
 223 Russell Korobkin & Rahul Rajkumar, The Genetic Information 
Nondiscrimination Act—A Half-Step toward Risk Sharing, 359 NEW ENG. J. MED. 335, 
336 (2008). 
 224 Id. The authors argue that  
GINA not only fails to protect the person with colonic polyps; it actually 
leaves him worse off than he would otherwise be. Because insurance 
companies may no longer make use of clearly relevant information such as 
family history in their risk assessment, they will rely even more heavily on 
current health status when setting rates, even when it has only slight value 
in predicting future illness. In a post-GINA world, not only will the very sick 
have even more trouble obtaining affordable insurance, but so will the mostly 
well. Second, while those who get bad news from genetic tests will rely on 
GINA to obtain health insurance at a subsidized rate, those whose genes put 
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Given the short period of time that a plaintiff has to file 
a complaint under GINA, many meritorious discrimination 
suits will likely be dismissed on procedural grounds. As in Title 
VII and ADA cases, employees have an obligation to exhaust 
all administrative remedies before they can bring suit under 
the act.229 Since the employment provisions of the legislation are 
regulated by the EEOC, employees must seek a right-to-sue 
letter from the agency within 90 days of the alleged 
discriminatory employment action or they will forfeit their 
right to bring a claim.230 Since a large number of eligible Title 
VII and ADA claims are dismissed each year for plaintiffs’ 
failure to exhaust administrative remedies, typically because 
the plaintiffs were unaware of the strict and extremely short 
deadlines involved, it is likely that many legitimate allegations 
of genetic discrimination will be dismissed for the same 
procedural reasons.231 
In addition to the gaps mentioned above, it is likely that 
additional protective legislation for workers will be required as 
biotechnology and medicine progress.232 Amendments to GINA 
likely will be necessary in the near future to accommodate 
rapid advancement in science. For example, many genetic tests 
currently require improvements in order to increase accuracy 
and effectiveness.233 While some tests are extremely precise, 
such as the screen for Huntington’s disease,234 scientists are still 
looking to advance the predictive performance of the test for 
cardiovascular disease (CVD).235 While a gene variant has been 
identified for CVD, using this information has not helped 
geneticists to predict its occurrence.236 Out of a study of 22,129 
women, “[a]dding the genotypic information to traditional risk 
factors—including family history—reclassified 2.6% of the 
women to different risk categories, but 63.4% of them were 
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incorrectly reclassified.”237 Similar problems have occurred in 
predictive studies for prostate cancer and Type 2 diabetes.238 
However, research in this area is continuously evolving. 
While other problems such as cost-effectiveness239 exist, it is 
likely that these types of genetic tests will become more 
accurate and more available for a host of diseases that may or 
may not be covered by the current form of GINA. 
Another example of an emerging scientific field with 
genetic discrimination potential is neuro-pharmacological 
enhancement, also referred to as “cosmetic neurology.”240 
Potential developments in this field offer “the prospect of 
improving the learning, memory, and attention skills of 
healthy individuals, well beyond the normal human range.”241 
The field of cosmetic neurology is fraught with scientific, legal, 
and ethical concerns; yet, with regards to employment, new 
forms of coercion and discrimination are feared.242 In particular, 
many are worried that the abuse will target behavioral traits 
such as limited attention span due to Attention Deficit 
Hyperactivity Disorder (“ADHD”). While ADHD can be caused 
by a range of factors including environmental agents, brain 
injury, food additives, and sugar, genetics plays a large role.243 
Indeed, “[s]tudies indicate that 25% of the close relatives in the 
families of ADHD children also have ADHD, whereas the rate 
is about 5% in the general population.”244 
Although ADHD has a strong link to genetics, GINA 
does not prevent employers from testing the memory skills or 
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attention spans of their workers.245 Here, the danger stems from 
the naturally unbalanced relationship that exists in at-will 
employment situations: the employer enjoys a much better 
bargaining position than his or her employees. Thus, workers 
could feel compelled to consume enhancing drugs, such as 
Adderral, to retain their jobs or to keep pace with those in the 
workforce who choose to consume these pharmaceuticals.246 
Eventually, this could result in discrimination, as separation 
forms between those who consume neurological enhancers and 
those who do not.247 While there certainly are situations where 
such skills are necessary to perform a job, as the science of 
pharmacology progresses, protections will be needed in the 
form of acts like GINA to guard employees from the pressure to 
medicate to maintain their positions.  
CONCLUSION 
Due to this country’s history of genetic discrimination, 
the GINA was a necessary piece of legislation. Now that GINA 
is in effect, Americans no longer need to fear potential 
discrimination from their insurers and employers, and thus 
will be more willing to take advantage of existing opportunities 
for genetic testing.248 However, while GINA fills in some of the 
gaps of prior federal legislation, the compromises made in its 
passage leave unprotected many genetically-based categories of 
illness.249 Furthermore, as medicine and technology inexorably 
advance, it is also likely that amendments to GINA will be 




 245 Appel, supra note 214, at 618. 
 246 Id. at 617. 
 247 Id. at 618. 
 248 Baruch & Hudson, supra note 9, at 436. 
 249 Miller, supra note 22, at 252-56. 
 250 See Appel, supra note 214, at 618. 
 † J.D. Candidate, Brooklyn Law School, 2010; B.S., Cornell University, 2005. 
I would like to thank the editors and staff of the Brooklyn Law Review for their time 
and assistance with this note. I would also like to give special thanks to Dr. Frederick 
Barken and Dr. Bruce Korf for their guidance and medical expertise. 
